Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1358894

Next Previous
Drug Profile

BI 1358894

Alternative Names: BI-1358894

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hydra Biosciences
  • Developer Boehringer Ingelheim; Hydra Biosciences
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action TRPC4 cation channel inhibitors; TRPC5 cation channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Borderline personality disorders; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 23 Feb 2024 Boehringer Ingelheim completes a phase-II clinical trials in Major depressive disorder (Treatment-experienced, Recurrent) in USA, Slovakia, Poland, Czech Republic, Spain, Russia, Japan, Hungary, Germany, France, Canada, Bulgaria, Australia, Argentina (PO) (NCT04521478) (EudraCT2019-004264-21)
  • 20 Feb 2024 Boehringer Ingelheim initiates a phase I pharmacokinetic trial (In volunteers) in Germany (PO) due to company decision (NCT05934942)
  • 12 Oct 2023 Boehringer Ingelheim completes a phase II trial in Post-traumatic stress disorder in the US, Sweden, Poland, Israel, Mexico, Germany, Finland, Croatia (PO) (NCT05103657; Eudra-CT-2021-003154-23)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top